Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study

Liver International : Official Journal of the International Association for the Study of the Liver
M KudoSheng-Long Ye

Abstract

Treatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed. Data from the multinational GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) registry evaluated differences in patient characteristics, practice patterns and outcomes in HCC across geographical regions in patients who received sorafenib. GIDEON is a non-randomised, observational registry study conducted in 39 countries across five global regions. HCC patients in whom a decision to treat with sorafenib was made in clinical practice and according to local practices were included. 3202 patients were evaluable for safety analysis: Asia-Pacific (n = 928), Japan (n = 508), Europe (n = 1113), USA (n = 563) and Latin America (n = 90). Patients in Japan had earlier-stage disease at initial diagnosis compared with patients in other regions (Barcelona Clinic Liver Cancer stage A; 43.7% vs 9.1-24.3%). Use of locoregional therapies before sorafenib, including transarterial chemoembolisation, was more common in Japan (84.4%) and Asia-Pacific (67.2%) compared with the USA (49.4%) and Europe (43.5%). Treatment patterns...Continue Reading

References

Jun 16, 2007·Gastroenterology·Hashem B El-Serag, K Lenhard Rudolph
Jul 19, 2008·World Journal of Gastroenterology : WJG·Abdel-Rahman El-Zayadi
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Jan 15, 2009·Liver International : Official Journal of the International Association for the Study of the Liver·Puneeta Tandon, Guadalupe Garcia-Tsao
Jan 18, 2011·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·E Maillard
Feb 4, 2012·Journal of Hepatology·Carlos Rodríguez de LopeJordi Bruix
Mar 20, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·UNKNOWN European Association for Study of Liver, UNKNOWN European Organisation for Research and Treatment of Cancer
Mar 20, 2012·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver, UNKNOWN European Organisation For Research And Treatment Of Cancer
Apr 28, 2012·Gastroenterology·Hashem B El-Serag
May 29, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Jing GaoYong-Bing Xiang
Aug 1, 2012·Seminars in Oncology·Riccardo Lencioni
Jun 6, 2014·Clinical Medicine Insights. Oncology·Avegail Flores, Jorge A Marrero

❮ Previous
Next ❯

Citations

Nov 22, 2016·The Cancer Journal·Lin MuJean-François Geschwind
Jun 24, 2017·Liver International : Official Journal of the International Association for the Study of the Liver·Jose D DebesLewis R Roberts
Dec 14, 2017·Liver Cancer·Masatoshi Kudo
Apr 24, 2018·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Shinsuke UchikawaKazuaki Chayama
Aug 1, 2018·Nature Reviews. Clinical Oncology·Josep M LlovetRichard S Finn
Mar 17, 2017·Targeted Oncology·Gillian M Keating
Dec 24, 2018·Expert Review of Anticancer Therapy·Bernard EscudierMasatoshi Kudo
Aug 13, 2020·Signal Transduction and Targeted Therapy·Ao HuangJian Zhou
Nov 11, 2017·Expert Review of Gastroenterology & Hepatology·Yousery NadaOmar Abdel-Rahman
Dec 10, 2020·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Hidenori ToyodaAmit G Singal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.